(Q34130569)

31 July 2017

1 reference

title

New approaches to antibody therapy (English)

1 reference

31 July 2017

1 reference

Weiner LM

1

1 reference

31 July 2017

Adams GP

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

53

1 reference

31 July 2017

6144-6151

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1204000

31 July 2017

0 references

cites work

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Making antibody fragments using phage display libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Clinical experience with CD64-directed immunotherapy. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Preliminary trial of specific targeting therapy against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Chemotactic monoclonal antibody conjugates: a comparison of four different f-Met-peptide-conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

90Yttrium antiferritin--a new therapeutic radiolabeled antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Targeting of cytotoxic cells with heterocrosslinked antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Paul Ehrlich: the founding of pediatric immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

A simple and improved method to generate human hybridomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204000

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204000

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference